World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
107
Citations
79244
World Ranking
6093
National Ranking
13

John F. Forbes publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where John F. Forbes sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 447 publications — 48th percentile

48% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

John F. Forbes D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where John F. Forbes sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 107 D-Index — 70th percentile

70% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

John F. Forbes is affiliated with the University of Limerick in Ireland and has a research portfolio primarily situated in the field of Medicine. Their work spans several subfields including Rehabilitation, Pulmonary and Respiratory Medicine, Neurology, Public Health, Environmental and Occupational Health, and Epidemiology.

The scientist has contributed notably to a range of topics, including:

  • Stroke Rehabilitation and Recovery
  • Acute Ischemic Stroke Management
  • Physical Activity and Health
  • Estrogen and related hormone effects
  • Advanced Breast Cancer Therapies
  • COVID-19 and healthcare impacts
  • Long-Term Effects of COVID-19

Notable recent papers by John F. Forbes include:

  • "Occupation and risk of severe COVID-19: prospective cohort study of 120 075 UK Biobank participants" (2020) published in Occupational and Environmental Medicine
  • "Occupation and risk of severe COVID-19: prospective cohort study of 120,075 UK Biobank participants" (2020) published in bioRxiv (Cold Spring Harbor Laboratory)
  • "The associations of sugar-sweetened, artificially sweetened and naturally sweet juices with all-cause mortality in 198,285 UK Biobank participants: a prospective cohort study" (2020) published in BMC Medicine
  • "Colchicine for prevention of vascular inflammation in Non-CardioEmbolic stroke (CONVINCE) - study protocol for a randomised controlled trial" (2021) published in European Stroke Journal
  • "Association Between Walking Pace and Stroke Incidence" (2020) published in Stroke

John F. Forbes frequently publishes in journals such as Cancer Research, Age and Ageing, International Journal of Stroke, HRB Open Research, and Occupational and Environmental Medicine.

Frequent collaborators include:

  • Sara Hayes
  • Jill P. Pell
  • Carlos Celis-Morales
  • Naveed Sattar
  • Cathal Walsh

Best Publications

  • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

    O. Abe;R. Abe;K. Enomoto;K. Kikuchi

  • Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

    A Goldhirsch;E P Winer;A S Coates;R D Gelber

  • Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

    C Focan;SM Steinberg;M Blichert-Toft;JF Forbes

  • Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.

    M Baum;A U Budzar;J Cuzick;J Forbes

  • Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer

    Anthony Howell

  • Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

    Christina Davies;Hongchao Pan;Jon Godwin;Richard Gray

  • Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial.

    D J Adam;J D Beard;T Cleveland;J Bell

  • A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

    Beat Thürlimann;Aparna Keshaviah;Alan S Coates

  • Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.

    Jack Cuzick;Ivana Sestak;Michael Baum;Aman U Buzdar

  • Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms

    Charles Mccollum;J. T. Powell;A. R. Brady;L. C. Brown

  • Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses

    M Baum;A Buzdar;J Cuzick;J Forbes

  • Overview of the main outcomes in breast-cancer prevention trials.

    J Cuzick;T Powles;U Veronesi;J Forbes

  • Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

    Alan S. Coates;Aparna Keshaviah;Beat Thürlimann;Henning Mouridsen

  • Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

    M Dowsett;JF Forbes;JF Forbes;Matti Hakama

  • Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

    RC Coombes;LS Kilburn;CF Snowdon;R Paridaens

  • Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen

    Mitch Dowsett;Jack Cuzick;Jim Ingle;Alan Coates

  • Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer

    Jack Cuzick;Mitch Dowsett;Silvia Pineda;Christopher Wale

  • Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study

    Mitch Dowsett;Jack Cuzick;Christopher Wale;John Forbes

  • First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial.

    J Cuzick;J Forbes;R Edwards;M Baum

  • Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

    Bernard Asselain;William Barlow;John Bartlett;Jonas Bergh

Frequent Co-Authors

Jack Cuzick
Jack Cuzick Queen Mary University of London
Alan S. Coates
Alan S. Coates University of Sydney
Anthony Howell
Anthony Howell University of Manchester
Richard D. Gelber
Richard D. Gelber Harvard University
Karen N. Price
Karen N. Price Frontier Science Foundation
Gordon D. Murray
Gordon D. Murray University of Edinburgh
Aron Goldhirsch
Aron Goldhirsch European Institute of Oncology
Mitch Dowsett
Mitch Dowsett Breast Cancer Research Foundation
Beat Thürlimann
Beat Thürlimann Kantonsspital St. Gallen
Marco Colleoni
Marco Colleoni European Institute of Oncology

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in Medicine doesn't always mean following a traditional path. There are several accessible online degrees and certifications that support different roles in healthcare, making it easier for students to find a pathway that aligns with their goals and financial circumstances.

For those interested in advanced nursing roles, searching for the cheapest dnp program options can help you earn a Doctor of Nursing Practice degree without a significant financial burden. If pharmacy is your passion, pursuing an online pharmacy degree offers flexibility and affordability compared to traditional campus programs.

Beyond clinical roles, online schools for health information management give students the skills to handle patient records and maintain healthcare data integrity—an essential part of modern medicine. You can learn more about pursuing these degrees by researching online schools for health information management.

Additionally, those looking to enter the administrative side of healthcare can find affordable training by reviewing medical coding certification cost. This pathway is ideal for individuals seeking a flexible and in-demand healthcare career without extensive schooling.

Best Scientists Citing John F. Forbes

Trending Scientists

Recently Published Articles